Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791216 | 0.94 | PARP1 (0.73) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL31397021 | 0.88 | PDE10A (0.69) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL1914469 | 0.88 | PDE10A (0.69) | PARP1PDE10APARP2TNKS2KMT2A | |
| Hydrochloric Acid SCHEMBL15575309 | 0.86 | PDE10A (0.68) | PARP1PDE10APARP2TNKS2KMT2A | |
| SCHEMBL30176973 | 0.85 | PARP1 (0.89) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL22857122 | 0.85 | PARP1 (0.89) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL28598382 | 0.85 | PARP1 (0.89) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL4852668 | 0.85 | PARP1 (0.69) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL14621928 | 0.85 | PARP1 (0.89) | PARP1PDE10APARP2HTR1AHTR7 | |
| SCHEMBL30176861 | 0.85 | PARP1 (0.89) | PARP1PDE10APARP2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PDE10A 2013/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.